Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the <scp>LANDMARK</scp> trial-Reference-Cited by-同舟云学术

Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

Published:2024-03-12 Issue:4 Volume:28 Page:580-590
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Kato Masanori¹,Ito Hidetoshi¹,Yamakawa Akane²,Kagimura Tatsuo²,Fukagawa Masafumi³^ORCID,Yamamoto Masahiro¹,Saito Yoshinori¹,Akizawa Tadao⁴^ORCID,Ogata Hiroaki¹⁵^ORCID

Affiliation:

1. Division of Nephrology, Department of Internal Medicine Showa University Northern Yokohama Hospital Yokohama Kanagawa Japan

2. The Translational Research Center for Medical Innovation Foundation for Biomedical Research and Innovation at Kobe Kobe Hyogo Japan

3. Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine Tokai University School of Medicine Isehara Kanagawa Japan

4. Division of Nephrology, Department of Medicine Showa University Graduate School of Medicine Shinagawa Tokyo Japan

5. Department of Medical Education Showa University Graduate School of Medicine Shinagawa Tokyo Japan

Abstract

AbstractIntroductionThe clinical benefits of aspirin in patients undergoing hemodialysis remain unclear.MethodsThe secondary analysis of the LANDMARK trial investigated whether aspirin use was associated with cardiovascular events (CVEs) and all‐cause mortality was performed. A total of 2135 patients at risk for vascular calcification were analyzed using a Cox proportional hazards model with propensity score matching.ResultsThe risk of CVEs was comparable between participants with aspirin use at baseline and those without at baseline, between participants with aspirin use during the study period and those without during the study period, and between participants with new aspirin prescription and those without aspirin use during the study period.ConclusionAspirin use was not significantly associated with a lower risk of CVEs in participants undergoing hemodialysis patients at risk of vascular calcification.

Funder

Bayer Yakuhin

Japan Society for the Promotion of Science

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.14123

Reference29 articles.

1. The heart and vascular system in dialysis

2. Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease

3. Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?

4. Aspirin Prescription and Outcomes in Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

5. Consistent Aspirin Use Associated with Improved Arteriovenous Fistula Survival among Incident Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study